- Home
- ARWR vs KYMR Comparison
ARWR vs KYMR Comparison
Compare ARWR & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | KYMR |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARWR | KYMR |
|---|---|---|
| Price | $70.94 | $89.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 23 |
| Target Price | $60.70 | ★ $101.43 |
| AVG Volume (30 Days) | ★ 3.3M | 1.3M |
| Earning Date | 11-25-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $829,448,000.00 | $43,735,000.00 |
| Revenue This Year | N/A | $20.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23258.15 | N/A |
| 52 Week Low | $9.57 | $19.45 |
| 52 Week High | $72.36 | $103.00 |
Technical Indicators
Market Signals| Indicator | ARWR | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 78.58 | 72.77 |
| Support Level | $60.29 | $85.00 |
| Resistance Level | $71.50 | $93.82 |
| Average True Range (ATR) | 5.14 | 4.56 |
| MACD | 1.73 | 2.49 |
| Stochastic Oscillator | 95.82 | 64.16 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.